Home  About us  Contact
 

Topiramate Therapy (topiramate + therapy)

Distribution by Scientific Domains
Medical Sciences100%

Selected Abstracts

Abnormal Wada and Neuropsychological Testing Results Due to Topiramate Therapy

EPILEPSIA, Issue 7 2000
Paul H. McCabe
Summary: A 46-year-old man experienced intractable seizures since childhood. Due to lack of response to antiepilepsy drugs (AEDs), he underwent a surgical evaluation that was consistent with seizure onset in the left medial temporal lobe. While on topiramate and carbamazepine, his preoperative neuropsychological scores and sodium amytal (Wada) scores were low and may have excluded him from surgery. Repeat testing on lamotrigine and carbamazepine showed improvement in his scores, allowing him to undergo surgery. Physicians must therefore be cautious in evaluating such test scores while a patient is on topiramate. [source]

Reversible Anorgasmia With Topiramate Therapy for Headache: A Report of 7 Patients

HEADACHE, Issue 9 2006
Christina Sun MD
Objective.,To describe 7 patients who developed new onset anorgasmia while using topiramate therapy for migraine prophylaxis. Background.,Topiramate is an effective drug for the prevention of migraine headaches. Though it is generally well tolerated, it may be associated with a dose-related anorgasmia. Methods.,Case reports Results.,Seven patients (5 women, 2 men), between the ages of 40 and 62, developed anorgasmia while using topiramate for headache prevention. Four women and 2 men had migraine without aura, and 1 woman had migraine with aura. None had a prior history of anorgasmia or sexual dysfunction. Doses associated with this side effect ranged from 45 to 200 mg daily. All subjects had symptom resolution. Six patients had resolution within 7 days of discontinuing or decreasing the medication; the exact time frame of resolution for the seventh patient is unknown. Conclusion.,In our series, anorgasmia was a reversible, dose-related adverse effect of topiramate. Physicians need to be aware of the potential for topiramate to cause sexual side effects, and should inquire about these symptoms in patients for whom this agent has been prescribed. [source]

Topiramate in the treatment of psoriasis: a pilot study

BRITISH JOURNAL OF DERMATOLOGY, Issue 1 2002
R. Ryback
SummaryBackground This study was initiated following a serendipitous finding in which a patient who presented with both a mood disorder and psoriasis experienced significant improvement of her psoriasis following treatment with topiramate. Objectives To determine the efficacy of topiramate for the treatment of psoriasis. Methods Seven other patients, six of whom presented with both mood disorders and psoriasis and one with psoriasis only, were treated in an open-label fashion with topiramate. Topiramate therapy was usually initiated at 15 mg day,1 and gradually titrated by 15 mg week,1 to an average final dose of 56 mg day,1. Patients were treated for a minimum of 4 months. Psoriasis severity was measured using the psoriasis area and severity index (PASI). Results For all patients, the mean PASI score decreased from 16·1 before treatment to 7·1. For patients exhibiting improvement, the mean PASI score decreased from 14·3 to 3·9. Conclusions These results represent the first known report of the efficacy of topiramate in the treatment of psoriasis. [source]

Reversible Anorgasmia With Topiramate Therapy for Headache: A Report of 7 Patients

HEADACHE, Issue 9 2006
Christina Sun MD
Objective.,To describe 7 patients who developed new onset anorgasmia while using topiramate therapy for migraine prophylaxis. Background.,Topiramate is an effective drug for the prevention of migraine headaches. Though it is generally well tolerated, it may be associated with a dose-related anorgasmia. Methods.,Case reports Results.,Seven patients (5 women, 2 men), between the ages of 40 and 62, developed anorgasmia while using topiramate for headache prevention. Four women and 2 men had migraine without aura, and 1 woman had migraine with aura. None had a prior history of anorgasmia or sexual dysfunction. Doses associated with this side effect ranged from 45 to 200 mg daily. All subjects had symptom resolution. Six patients had resolution within 7 days of discontinuing or decreasing the medication; the exact time frame of resolution for the seventh patient is unknown. Conclusion.,In our series, anorgasmia was a reversible, dose-related adverse effect of topiramate. Physicians need to be aware of the potential for topiramate to cause sexual side effects, and should inquire about these symptoms in patients for whom this agent has been prescribed. [source]